Viking Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 27
- Market Cap
- $6.8B
- Introduction
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
VK2735 for Weight Management Phase 2
- Conditions
- Weight Loss
- Interventions
- Biological: VK2735Biological: Placebo
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Viking Therapeutics, Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT06068946
- Locations
- 🇺🇸
Viking Clinical Site #107, Port Orange, Florida, United States
🇺🇸Viking Clinical Site #101, Austin, Texas, United States
🇺🇸Viking Clinical Site #114, Long Beach, California, United States
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
- Conditions
- NASHWeight Loss
- Interventions
- Biological: PlaceboBiological: VK2735Drug: VK2735 DrugDrug: VK2735 Placebo
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Viking Therapeutics, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT05203237
- Locations
- 🇦🇺
Viking Clinical Site, Adelaide, South Australia, Australia
A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN
- Conditions
- Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
- Interventions
- Drug: VK0214Other: Placebo
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Viking Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04973657
- Locations
- 🇫🇷
Viking Clinical Site 214, Bordeaux, France
🇺🇸Viking Clinical Site 205, Seattle, Washington, United States
🇮🇹Viking Clinical Site 210, Milano, Italy
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: VK2809Drug: Placebos
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Viking Therapeutics, Inc.
- Target Recruit Count
- 248
- Registration Number
- NCT04173065
- Locations
- 🇺🇸
Viking Clinical Site 148, Philadelphia, Pennsylvania, United States
🇺🇸Viking Clinical Site 317, Seattle, Washington, United States
🇺🇸Viking Clinical Site 160, Las Vegas, Nevada, United States
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
- Conditions
- HyperlipidemiaNAFLD
- Interventions
- Drug: PlaceboDrug: VK2809
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Viking Therapeutics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT02927184
- Locations
- 🇺🇸
Wake Research Associcates, LLC., Raleigh, North Carolina, United States
🇺🇸Flint Clinical Research, PLLC, Flint, Michigan, United States
🇺🇸SC Clinical Research, Garden Grove, California, United States
Acute Hip Fracture Study in Patients 65 Years or Greater
- Conditions
- Hip Fractures
- Interventions
- Drug: PlaceboDrug: VK5211
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Viking Therapeutics, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT02578095
- Locations
- 🇺🇸
Infinite Clinical Research, Doral, Florida, United States
🇭🇺Jósa András Oktató Kórház Traumatológiai és Kézsebészeti Osztály, Nyíregyháza, Hungary
🇭🇺SZTE ÁOK Traumatológiai Klinika, Szeged, Hungary